葡萄酸依诺沙星 | 104142-71-4

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 喹诺酮类药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 葡萄酸依诺沙星
• 英文名称: Enoxacin gluconate
• 英文别名: 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid
• CAS: 104142-71-4
• 化学式: C21H29FN4O10
• 分子量: 516.5
• InChiKey: UQCAODSJNCBXEG-IFWQJVLJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.83
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  224
• 氢给体数：
  8
• 氢受体数：
  15

文献信息

• Salts of antimicrobial naphthyridine and quinoline compounds and their production
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0067666A1

  公开（公告）日：1982-12-22

  There are disclosed compounds having the following general formula C: wherein X is N or CH and Z is galacturonic, aspartic, gluconic or glutamic acid; as well as processes for producing these compounds by reacting the acid Z with the other component. The acid addition salts of formula C are, unlike other acid addition salts of the active compound, suitable for parenteral administration when the active compound is used as an antibacterial agent.

  本发明公开了具有以下通式 C. 的化合物，其中 X 是 N 或 CH，Z 是半乳糖醛酸、天冬氨酸、葡糖酸或谷氨酸： 其中 X 是 N 或 CH，Z 是半乳糖醛酸、天冬氨酸、葡萄糖酸或谷氨酸；以及通过酸 Z 与其他成分反应生产这些化合物的工艺。与活性化合物的其他酸加成盐不同，式 C 的酸加成盐在活性化合物用作抗菌剂时适合肠外给药。
• Controlled release dosage form
  申请人：TRIASTEK, INC.

  公开号：US10143626B2

  公开（公告）日：2018-12-04

  The present invention generally relates to a pharmaceutical dosage form and controlled release of biologically active agents, diagnostic agents, reagents, cosmetic agents, and agricultural/insecticide agents. In one embodiment, the dosage form has a substrate that forms a compartment, wherein the substrate includes at least a first piece and a second piece, wherein the first piece operably links to the second piece. The dosage form contains a drug content that is loaded into the compartment. The dosage form also has a releaser operably linked to the substrate which upon contact with water or body fluid is capable of separating the first and second piece to open the compartment and release the drug content.

  本发明一般涉及一种药物剂型和生物活性制剂、诊断制剂、试剂、化妆品制剂和农用/杀虫剂制剂的控制释放。在一个实施方案中，该剂型具有形成隔室的基质，其中基质至少包括第一片和第二片，其中第一片与第二片可操作地连接。剂型含有装入隔室的药物成分。该剂型还具有与基质可操作连接的释放器，该释放器在与水或体液接触时能够分离第一和第二片，从而打开隔室并释放药物成分。
• Oral drug dosage forms having desired drug release profiles and uses thereof
  申请人：Triastek, Inc.

  公开号：US10258575B2

  公开（公告）日：2019-04-16

  The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

  本公开提供了一种用于口服的稳定固体药物剂型。该剂型包括至少形成一个小室的基质和装入小室的药物成分。该剂型的设计使药物内容物中的活性药物成分以可控方式释放。
• Compartmented pharmaceutical dosage forms
  申请人：Triastek, Inc.

  公开号：US10363220B2

  公开（公告）日：2019-07-30

  The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

  本公开提供了一种用于口服的稳定固体药物剂型。该剂型包括至少形成一个小室的基质和装入小室的药物成分。该剂型的设计使药物内容物中的活性药物成分以可控方式释放。
• Oral drug dosage form comprising drug in the form of nanoparticles
  申请人：Triastek, Inc.

  公开号：US10973767B2

  公开（公告）日：2021-04-13

  The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

  本公开提供了一种用于口服的稳定固体药物剂型。该剂型包括至少形成一个小室的基质和装入小室的药物成分。该剂型的设计使药物内容物中的活性药物成分以可控方式释放。